129 related articles for article (PubMed ID: 28447743)
1. Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer.
Tang Y; Cui X; Xiao H; Qi S; Hu X; Yu Q; Shi G; Zhang X; Gu J; Yu Y; Wang L; Li Y
Mol Med Rep; 2017 May; 15(5):2659-2664. PubMed ID: 28447743
[TBL] [Abstract][Full Text] [Related]
2. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
3. MUC1 serum assays in breast cancer: tumor specificities and reference levels.
Bjerner J; Norum LF; Nilsson O; Nustad K
Tumour Biol; 2002; 23(6):315-23. PubMed ID: 12677089
[TBL] [Abstract][Full Text] [Related]
4. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli.
Tang Y; Wang L; Zhang P; Wei H; Gao R; Liu X; Yu Y; Wang L
Clin Vaccine Immunol; 2010 Dec; 17(12):1903-8. PubMed ID: 20876819
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1).
Isla Larrain M; Demichelis S; Crespo M; Lacunza E; Barbera A; Cretón A; Terrier F; Segal-Eiras A; Croce MV
J Exp Clin Cancer Res; 2009 Aug; 28(1):121. PubMed ID: 19715603
[TBL] [Abstract][Full Text] [Related]
6. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
7. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer.
Hamanaka Y; Suehiro Y; Fukui M; Shikichi K; Imai K; Hinoda Y
Int J Cancer; 2003 Jan; 103(1):97-100. PubMed ID: 12455059
[TBL] [Abstract][Full Text] [Related]
8. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis.
Rabassa ME; Croce MV; Pereyra A; Segal-Eiras A
BMC Cancer; 2006 Oct; 6():253. PubMed ID: 17064405
[TBL] [Abstract][Full Text] [Related]
9. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.
Croce MV; Isla-Larrain M; Tur R; Rabassa ME; Segal-Eiras A
Clin Exp Metastasis; 2004; 21(2):139-47. PubMed ID: 15168731
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response against tumoral mucin 1 (MUC1) in breast cancer patients.
Isla Larrain MT; Colussi AG; Demichelis SO; Barbera A; Cretón A; Segal-Eiras A; Croce MV
Int J Biol Markers; 2013 Sep; 28(3):318-25. PubMed ID: 23828406
[TBL] [Abstract][Full Text] [Related]
11. Use of CA15‑3 for screening breast cancer: An antibody‑lectin sandwich assay for detecting glycosylation of CA15‑3 in sera.
Choi JW; Moon BI; Lee JW; Kim HJ; Jin Y; Kim HJ
Oncol Rep; 2018 Jul; 40(1):145-154. PubMed ID: 29749490
[TBL] [Abstract][Full Text] [Related]
12. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1).
von Mensdorff-Pouilly S; Gourevitch MM; Kenemans P; Verstraeten AA; van Kamp GJ; Kok A; van Uffelen K; Snijdewint FG; Paul MA; Meijer S; Hilgers J
Tumour Biol; 1998; 19(3):186-95. PubMed ID: 9591045
[TBL] [Abstract][Full Text] [Related]
13. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer.
Nakamura H; Hinoda Y; Nakagawa N; Makiguchi Y; Itoh F; Endo T; Imai K
J Gastroenterol; 1998 Jun; 33(3):354-61. PubMed ID: 9658314
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening.
Laidi F; Bouziane A; Errachid A; Zaoui F
Asian Pac J Cancer Prev; 2016; 17(1):335-9. PubMed ID: 26838233
[TBL] [Abstract][Full Text] [Related]
15. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women.
Richards ER; Devine PL; Quin RJ; Fontenot JD; Ward BG; McGuckin MA
Cancer Immunol Immunother; 1998 Jul; 46(5):245-52. PubMed ID: 9690452
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival.
Kurtenkov O; Klaamas K; Mensdorff-Pouilly S; Miljukhina L; Shljapnikova L; Chuzmarov V
Acta Oncol; 2007; 46(3):316-23. PubMed ID: 17450466
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
Zheng H; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
[TBL] [Abstract][Full Text] [Related]
19. Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis.
Jiang X; Guo D; Li W; Yu T; Zhou J; Gong J
Mol Med Rep; 2017 Mar; 15(3):1123-1134. PubMed ID: 28112378
[TBL] [Abstract][Full Text] [Related]
20. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
